tiprankstipranks
Trending News
More News >
Vitrolife AB (SE:VITR)
:VITR
Advertisement

Vitrolife AB (VITR) AI Stock Analysis

Compare
1 Followers

Top Page

SE:VITR

Vitrolife AB

(VITR)

Select Model
Select Model
Select Model
Neutral 67 (OpenAI - 4o)
Rating:67Neutral
Price Target:
kr157.00
▲(4.11% Upside)
Vitrolife AB's overall stock score reflects strong financial stability and profitability, supported by positive technical indicators. However, high valuation metrics and recent revenue and cash flow declines pose risks. The company's strategic focus and regional growth, particularly in the Americas, are positive, but challenges such as currency impacts and increased expenses need to be addressed.

Vitrolife AB (VITR) vs. iShares MSCI Sweden ETF (EWD)

Vitrolife AB Business Overview & Revenue Model

Company DescriptionVitrolife AB (publ), a medical device company, develops, produces, and markets products for assisted reproduction. It provides oocyte retrieval needles; sperm processing; in vitro fertilization media and oil; micromanipulation pipettes; labware; incubators; cryopreservation; and preimplantation genetic testing products. The company also offers EmbryoScope and Primo Vision time-lapse systems; time-lapse dishes; evaluation tools for time-lapse systems; and Octax laser and imaging systems, as well as log and guard systems and wireless sensors. It operates in Europe, the Middle East, and Africa; Asia; Japan and Pacific; and North and South America. The company was formerly known as Scandinavian IVF Science and changed its name to Vitrolife AB (publ) in 1998. Vitrolife AB (publ) was founded in 1994 and is headquartered in Gothenburg, Sweden.
How the Company Makes MoneyVitrolife generates revenue through multiple key streams related to its core offerings in the fertility market. The primary revenue source comes from the sale of its specialized culture media and consumables, which are essential for embryo culture and preservation during IVF treatments. Additionally, the company earns income from laboratory equipment sales, including incubators and other high-tech devices used in ART clinics. A significant part of its revenue is also derived from partnerships with fertility clinics and hospitals, where they provide ongoing support, training, and maintenance for their products. Furthermore, Vitrolife invests in research and development to innovate and expand its product portfolio, which helps in maintaining a competitive edge and attracting new customers, ultimately contributing to its overall earnings.

Vitrolife AB Earnings Call Summary

Earnings Call Date:Oct 23, 2025
(Q3-2025)
|
% Change Since: |
Next Earnings Date:Feb 03, 2026
Earnings Call Sentiment Neutral
The earnings call reflects a company that is navigating difficult macroeconomic conditions with strategic investments and strong growth in certain regions, particularly the Americas. However, challenges such as currency impacts, regional difficulties in China, and increased operating expenses weigh on the overall performance.
Q3-2025 Updates
Positive Updates
Organic Growth Amid Challenges
Vitrolife delivered a 5% organic growth in local currencies, excluding discontinued business, despite facing macroeconomic and geopolitical challenges in the reproductive health industry.
Strong Performance in Americas
Sales in the Americas increased by 11% in local currencies with strong growth across the entire portfolio and in all markets, marking the strongest quarter in 11 quarters.
Stable Gross and EBITDA Margins
Gross margin slightly increased to 58.9%, and EBITDA was SEK 253 million, with an EBITDA margin of 30.3%, showing resilience despite negative currency impacts.
Positive Developments in EMEA and APAC
EMEA showed a 4% growth in local currencies, excluding discontinued business, and APAC recorded its first positive quarter of the year with 1% organic growth.
Operational Cash Flow
The company reported a strong operating cash flow of SEK 255 million, benefiting from positive contributions from net working capital.
Negative Updates
Currency Impact on Financials
Currency effects led to a 4% decrease in sales in SEK and a decrease in the gross margin from 58.6% to 58.1% year-to-date.
Challenges in China
Despite improved reimbursement, China continues to face depressed cycles, contributing to a slowdown in the APAC region.
Increased Operating Expenses
Operating expenses were SEK 40 million higher year-over-year due to strategic investments, particularly in IT and digitalization, despite a decrease compared to Q2.
Flat Sales in EMEA
EMEA sales declined by 2% in local currencies and by 6% in SEK, impacted by currency effects and geopolitical situations in the Middle East.
Company Guidance
In the Q3 2025 earnings call, Vitrolife provided detailed financial and operational guidance despite challenging macroeconomic conditions. The company achieved 5% organic growth in local currencies, excluding discontinued business, with sales totaling SEK 835 million. The gross margin remained stable at 58.9%, while EBITDA reached SEK 253 million, translating to a 30.3% EBITDA margin. Notably, the Americas region showed strong performance with an 11% sales increase in local currencies, contributing 33% of total sales. EMEA delivered sales of SEK 309 million with a 4% organic growth, and APAC recorded a 1% increase, marking its first positive quarter year-to-date. The company's operating cash flow was SEK 255 million, supported by effective working capital management. Looking forward, Vitrolife emphasized strategic investments in sales and marketing, particularly in the U.S., and continued focus on innovation and operational excellence to navigate the economic landscape.

Vitrolife AB Financial Statement Overview

Summary
Vitrolife AB shows strong profitability with healthy margins, but recent declines in revenue and free cash flow pose potential risks. The balance sheet is robust with low leverage and strong equity, providing financial stability. Overall, the company is financially stable but needs to address recent growth challenges.
Income Statement
65
Positive
Vitrolife AB's income statement shows a mixed performance. The TTM data indicates a slight decline in revenue growth rate at -1.94%, which is concerning. However, the company maintains a healthy gross profit margin of 58.83% and a net profit margin of 12.86%, reflecting stable profitability. The EBIT and EBITDA margins are also robust at 19.36% and 25.60% respectively, although they have decreased compared to the previous year. Overall, the company demonstrates strong profitability, but the recent revenue decline is a potential risk.
Balance Sheet
72
Positive
Vitrolife AB's balance sheet is solid with a low debt-to-equity ratio of 0.15, indicating conservative leverage. The return on equity (ROE) is modest at 3.42%, suggesting room for improvement in generating returns for shareholders. The equity ratio is strong, with stockholders' equity comprising a significant portion of total assets, indicating financial stability. Overall, the balance sheet reflects a stable financial position with low leverage and good equity strength.
Cash Flow
60
Neutral
The cash flow statement reveals some challenges for Vitrolife AB. The free cash flow growth rate is negative at -6.63%, indicating a decline in cash generation. However, the operating cash flow to net income ratio is healthy at 1.08, suggesting efficient cash conversion from earnings. The free cash flow to net income ratio is also strong at 0.93, indicating good cash flow relative to profits. Despite the decline in free cash flow growth, the company maintains a solid cash flow position relative to its net income.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue3.54B3.61B3.51B3.23B1.68B1.25B
Gross Profit2.08B2.14B1.98B1.78B1.05B767.67M
EBITDA906.00M783.00M-3.19B993.00M579.60M438.65M
Net Income455.00M513.00M-3.85B394.00M341.00M286.85M
Balance Sheet
Total Assets16.86B17.45B16.33B20.55B19.43B2.31B
Cash, Cash Equivalents and Short-Term Investments921.00M1.14B861.00M578.00M630.09M973.57M
Total Debt1.99B2.09B2.09B2.23B2.48B62.40M
Total Liabilities3.57B3.81B3.61B3.81B4.09B288.07M
Stockholders Equity13.28B13.64B12.72B16.74B15.32B2.01B
Cash Flow
Free Cash Flow648.00M907.00M638.00M549.00M321.86M336.36M
Operating Cash Flow694.00M907.00M757.00M636.00M384.31M356.45M
Investing Cash Flow-291.00M-377.00M-124.00M-144.00M-6.52B-20.22M
Financing Cash Flow-281.00M-286.00M-300.00M-582.00M5.75B-26.61M

Vitrolife AB Technical Analysis

Technical Analysis Sentiment
Positive
Last Price150.80
Price Trends
50DMA
136.82
Positive
100DMA
139.47
Positive
200DMA
157.94
Negative
Market Momentum
MACD
3.61
Negative
RSI
66.13
Neutral
STOCH
86.90
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:VITR, the sentiment is Positive. The current price of 150.8 is above the 20-day moving average (MA) of 140.52, above the 50-day MA of 136.82, and below the 200-day MA of 157.94, indicating a neutral trend. The MACD of 3.61 indicates Negative momentum. The RSI at 66.13 is Neutral, neither overbought nor oversold. The STOCH value of 86.90 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:VITR.

Vitrolife AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
kr4.49B29.7218.65%1.33%3.45%4.22%
kr20.47B46.403.34%0.73%-1.29%
kr6.28B210.071.32%8.39%-85.36%
€60.41B101.8431.78%0.36%5.74%30.96%
kr60.66B29.536.91%2.07%6.74%21.40%
$1.66B-15.03%-21.56%70.41%
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:VITR
Vitrolife AB
150.80
-90.82
-37.59%
SE:GETI.B
Getinge
222.90
30.69
15.97%
SE:BICO
BICO Group AB Class B
22.22
-16.32
-42.35%
SE:CEVI
CellaVision AB
185.00
-58.40
-23.99%
SE:XVIVO
Xvivo Perfusion AB
193.20
-268.80
-58.18%
SE:SECT.B
Sectra AB Class B
313.40
24.27
8.39%

Vitrolife AB Corporate Events

Vitrolife AB Reports Mixed Q3 2025 Results Amid Currency Challenges
Oct 23, 2025

Vitrolife AB reported a mixed financial performance for Q3 2025, with a 3% growth in sales in local currencies but a 4% decrease in SEK due to currency impacts. The company saw significant growth in the Americas and in its technologies and consumables product groups, despite a challenging currency environment affecting margins. The company also signed a EUR 300 million loan agreement to refinance existing debt and support general corporate purposes, indicating strategic financial management amidst currency challenges.

The most recent analyst rating on (SE:VITR) stock is a Hold with a SEK147.00 price target. To see the full list of analyst forecasts on Vitrolife AB stock, see the SE:VITR Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 23, 2025